+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028

  • ID: 4833463
  • Drug Pipelines
  • September 2019
  • Region: Global
  • 118 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

‘Spinocerebellar Ataxia (SCA) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SCA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Spinocerebellar Ataxia (SCA) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017-2028

Spinocerebellar Ataxia (SCA) - Disease Understanding and Treatment Algorithm

Spinocerebellar Ataxia is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

The Spinocerebellar Ataxia (SCA) market report gives the thorough understanding of the Spinocerebellar Ataxia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Spinocerebellar Ataxia in the US, Europe and Japan.

Spinocerebellar Ataxia Epidemiology

The Spinocerebellar Ataxia (SCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Spinocerebellar Ataxia and type-specific prevalent cases) scenario of Spinocerebellar Ataxia (SCA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to the publisher, the total number of prevalent cases of Spinocerebellar Ataxia (SCA) in 7 MM was found to be 42,043, in the year 2017.

Spinocerebellar Ataxia Drug Chapters

This segment of the Spinocerebellar Ataxia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The SCA market forecast provided in the report solely focuses on the market revenue generated by the pharmacological treatment (including off-label symptomatic therapies, such as Neuro-protective agents, Nicotine Receptor Agonists, Serotonergic Therapy, and GABAergic Therapy) used for SCA management in the diagnosed cases. Detailed chapter for upcoming therapies like Troriluzole (BHV-4157; Biohaven Pharmaceuticals) and KPS-0373 (Rovatirelin; Kissei Pharmaceuticals) have been covered in the report.

Spinocerebellar Ataxia Market Outlook

The Spinocerebellar Ataxia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, the market of Spinocerebellar Ataxia in 7MM was found to be USD 30.28 Million in 2017, and is expected to further increase during the course of the study period from 2017-2028. Among the 7MM, Japan accounts for the largest market size of Spinocerebellar Ataxia, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and the United States.

Spinocerebellar Ataxia Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Spinocerebellar Ataxia Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Spinocerebellar Ataxia Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Spinocerebellar Ataxia Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Spinocerebellar Ataxia market
  • Organize sales and marketing efforts by identifying the best opportunities for Spinocerebellar Ataxia market
  • To understand the future market competition in the Spinocerebellar Ataxia market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

1. Key Insights

2. Spinocerebellar Ataxia Market Overview at a Glance
2.1. Market Share (%) Distribution of Spinocerebellar Ataxia in 2017
2.2. Market Share (%) Distribution of Spinocerebellar Ataxia in 2028

3. Disease Background and Overview
3.1. Introduction
3.2. Subtypes of SCA
3.2.1. SCA1
3.2.2. SCA2
3.2.3. SCA3
3.2.4. SCA6
3.2.5. SCA7
3.3. Causes and risk factors
3.4. History
3.5. Signs and Symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.8. Biomarkers
3.8.1. Neuroimaging biomarkers
3.8.2. Oculomotor biomarkers
3.8.3. Biological biomarkers

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Patient Population of Spinocerebellar Ataxia

5. Country Wise-Epidemiology of Spinocerebellar Ataxia
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
5.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
5.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
5.2. EU5 Countries
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
5.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
5.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
5.4. France
5.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
5.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
5.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
5.5. Italy
5.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
5.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
5.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
5.6. Spain
5.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
5.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
5.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
5.7. United Kingdom
5.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
5.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
5.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
5.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
5.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

6. Treatments
6.1. Potential treatments
6.2. U.S. Guidelines
6.2.1. Local Susceptibility of Host Tissue
6.3. Europe Guidelines
6.4. Management of Spinocerebellar Ataxia

7. Unmet Needs

8. Emerging Therapies
8.1. Troriluzole: Biohaven Pharmaceuticals
8.1.1. Product Description
8.1.2. Other Development Activities
8.1.3. Clinical Development
8.1.4. Safety and Efficacy
8.1.5. Product Profile
8.2. Rovatirelin (KPS-0373): Kissei Pharmaceutical
8.2.1. Product Description
8.2.2. Clinical Development
8.2.3. Safety and Efficacy
8.2.4. Product Profile

9. Other Promising Candidates
9.1. IB1001: IntraBio
9.1.1. Product Description
9.1.2. Other Development Activities
9.1.3. Clinical Development
9.1.4. Product Profile
9.2. Stemchymal: Steminent Biotherapeutics
9.2.1. Product Description
9.2.2. Other Development Activities
9.2.3. Clinical Development
9.2.4. Safety and Efficacy
9.2.5. Product Profile

10. Spinocerebellar Ataxia: 7 Major Market Analysis
10.1. Key Findings
10.2. Market Size of Spinocerebellar Ataxia in 7MM

11. The United States Market Outlook
11.1. United States Market Size
11.1.1. Total Market size of Spinocerebellar Ataxia
11.1.2. Market Size by Line of Therapies

12. EU-5 Countries: Market Outlook
12.1. Germany
12.1.1. Total Market size of Spinocerebellar Ataxia in Germany
12.1.2. Market Size by Line of Therapies
12.2. France
12.2.1. Total Market Size of Spinocerebellar Ataxia
12.2.2. Market Size by Line of Therapies
12.3. Italy
12.3.1. Total Market Size of Spinocerebellar Ataxia
12.3.2. Market Size by Line of Therapies
12.4. Spain
12.4.1. Total Market Size of Spinocerebellar Ataxia
12.4.2. Market Size by Line of Therapies
12.5. The United Kingdom
12.5.1. Total Market Size of Spinocerebellar Ataxia
12.5.2. Market Size by Line of Therapies
12.6. Japan: Market Outlook
12.7. Japan Market Size
12.7.1. Total Market Size of Spinocerebellar Ataxia
12.7.2. Market Size by Line of Therapies

13. Market Drivers

14. Market Barriers

15. Appendix
15.1. Report Methodology

16. Publisher Capabilities

17. Disclaimer

18. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Troriluzole (Biohaven Pharmaceuticals)
  • Rovatirelin (Kissei Pharmaceutical)
  • IB1001 (IntraBio)
  • Stemchymal (Steminent Biotherapeutics)
Note: Product cover images may vary from those shown
Adroll
adroll